|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.25 TWD | +1.79% |
|
-.--% | - |
| 27/04 | UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 12/25/12 | UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2025 | CI |
| Market Cap | 168.32Cr 5.22Cr 4.52Cr 4.22Cr 3.86Cr 7.27Cr 497.5Cr 7.38Cr 49Cr 19Cr 248.89Cr 20Cr 19Cr 828.93Cr | P/E 2024 |
-9.63x | P/E 2025 | -5.68x |
|---|---|---|---|---|---|
| Enterprise Value | 197.21Cr 6.11Cr 5.29Cr 4.95Cr 4.52Cr 8.52Cr 582.89Cr 8.65Cr 58Cr 23Cr 291.61Cr 23Cr 22Cr 971.21Cr | EV / Sales 2024 |
3.58x | EV / Sales 2025 | 3.83x |
| Free-Float |
27.79% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | +1.79% |
| 3 years | 10 |  | 38.5 |
| 5 years | 10 | | 199.22 |
| 10 years | 8.34 | | 288.72 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jung Kuang Yang
CEO | Chief Executive Officer | - | - |
Meng Han Hsu
DFI | Director of Finance/CFO | - | 11/04/2016 |
Ying Yun Fan
ADM | Chief Administrative Officer | - | 01/03/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Ying Yun Fan
BRD | Director/Board Member | - | 30/06/2020 |
Yan Ning Kuo
BRD | Director/Board Member | - | 30/06/2020 |
Yao Hui Wei
BRD | Director/Board Member | - | 30/06/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.79% | -.--% | -.--% | -57.88% | 5.22Cr | |
| +3.90% | +9.86% | +96.91% | +136.30% | 1,09800Cr | |
| +0.99% | +2.91% | +51.05% | +52.06% | 63TCr | |
| +0.78% | +1.17% | +25.21% | +63.74% | 44TCr | |
| +0.28% | +4.53% | +51.81% | +41.01% | 37TCr | |
| +0.22% | +2.09% | +32.47% | +40.12% | 30TCr | |
| +0.49% | +2.61% | +9.15% | +9.21% | 25TCr | |
| +1.52% | +10.12% | +44.75% | +59.20% | 23TCr | |
| +1.14% | +0.70% | -3.98% | -50.09% | 21TCr | |
| -0.11% | +1.46% | +11.43% | +66.32% | 16TCr | |
| Average | +0.59% | +1,491.93% | +31.88% | +36.00% | 36.84TCr | |
| Weighted average by Cap. | +0.20% | +1,331.48% | +52.07% | +68.84% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 54Cr 1.67Cr 1.45Cr 1.35Cr 1.23Cr 2.33Cr 159.26Cr 2.36Cr 16Cr 6.22Cr 80Cr 6.27Cr 6.13Cr 265.36Cr | 51Cr 1.59Cr 1.38Cr 1.29Cr 1.18Cr 2.22Cr 152.05Cr 2.26Cr 15Cr 5.94Cr 76Cr 5.99Cr 5.86Cr 253.34Cr |
| Net income | -17Cr -54.08L -46.82L -43.76L -40L -75.37L -52Cr -76.55L -5.13Cr -2.01Cr -26Cr -2.03Cr -1.99Cr -86Cr | -30Cr -91.82L -79.49L -74.3L -67.9L -1.28Cr -88Cr -1.3Cr -8.71Cr -3.42Cr -44Cr -3.45Cr -3.37Cr -145.91Cr |
| Net Debt | 25Cr 76.34L 66.09L 61.78L 56.46L 1.06Cr 73Cr 1.08Cr 7.24Cr 2.84Cr 36Cr 2.87Cr 2.8Cr 121.32Cr | 29Cr 89.53L 77.51L 72.44L 66.21L 1.25Cr 85Cr 1.27Cr 8.5Cr 3.33Cr 43Cr 3.36Cr 3.29Cr 142.27Cr |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- 6562 Stock
Select your edition
All financial news and data tailored to specific country editions
